Company News

FEATURED POST

June 21, 2021

PREFECT Trial Outcomes Demonstrate MyoStrain® Ability to Detect & Predict Early Cardiotoxicity in Cancer Patients Undergoing Chemotherapy

A new pivotal article validated Myocardial Solutions technology MyoStrain® (fSENC) for the early detection and prediction of cardiotoxicity (heart damage). The article was published in published in Circulation: Cardiovascular Imaging, Journal of the American Heart Association–one of the most ...

Read more >

July 22, 2021

New Study Demonstrates MyoStrain® Ability to Differentiate Between Varying Levels of Left Ventricular Hypertrophy to Help Optimize Therapy

Myocardial Solutions’ software platform, MyoStrain, was featured in a new Journal of Cardiovascular Magnetic Resonance publication evaluating a multiparametric assessment of left ventricular hypertrophy (LVH). LVH, which can be a result of an array of diseases and conditions, makes determining the..

Read more >

July 12, 2021

New Study Demonstrates MyoStrain® Ability to Detect Subclinical Cardiac Dysfunction in Patients with Wilson Disease

A recent study published in the Journal of Cardiovascular Magnetic Resonance featured Myocardial Solutions’ technology MyoStrain, where MyoStrain was used to examine myocardial tissue function in Wilson Disease (WD) patients. WD, a storage disease that results in...

Read more >

May 13, 2021

MyoStrain® Provides Rapid, Accurate Assessment to Help Clinicians Detect Myocardial Ischemia and Rule Out Obstructive Coronary Artery Disease in Acute Chest Pain Patients

Myocardial Solutions (“MSI”) technologies MyoStrain® (fSENC) was featured in a newly published article exploring the effectiveness of cardiovascular magnetic resonance (CMR) and segmental strain to detect ischemia in patients suspected of obstructive coronary artery disease (CAD)...

Read more >

April 28, 2021

MyoStrain®, MyoStress™ Rapid Hyperventilation Breath-hold Maneuver Enables First-of-its-Kind Needle-Free Stress Protocol for the Accurate Detection of Myocardial Ischemia

A new peer-reviewed study accepted in the Journal of the American College of Cardiology: Cardiovascular Imaging validated Myocardial Solutions (“MSI”) technologies MyoStrain and MyoStress in a new stress testing protocol utilizing a hyperventilation breath-hold (HVBH) maneuver to accurately ...

Read more >

April 20, 2021

MyoStrain® Provides Quantitative Heart Failure Risk Assessment to Help Clinicians Individualize and Monitor Treatment in Asymptomatic Patients with Non-Ischemic Cardiomyopathy

A new article published in the Journal of Cardiovascular Magnetic Resonance utilized MyoStrain (fast-SENC) to accurately risk-stratify asymptomatic cardiac patients across multiple disease states. The article demonstrated MyoStrain’s clinical utility as a critical risk stratification tool to ...

Read more >

February 21, 2021

MyoStrain® and MyoStress™ Presented in Three New Abstracts at SCMR 2021

Myocardial Solutions, Inc. (“MSI”) attended the Society for Cardiovascular Magnetic Resonance’s (“SCMR”) 24th Annual Scientific Sessions, held virtually February 18-20, 2021. This year, SCMR main topics focused on new and traditional use cases of CMR, as well as exploring the use of CMR ...

Read more >

February 17, 2021

Abstract Posters and Presentations Featuring MyoStrain® at SCMR Virtual Scientific Sessions 2021

Myocardial Solutions,Inc. (“MSI”) will attend the Society for Cardiovascular Magnetic Resonance’s (“SCMR”) 24th annual scientific sessions virtually from February 18-21, 2021. The event focuses on highlighting breakthrough developments in new cardiovascular magnetic resonance (CMR) techniques ...

Read more >

February 11, 2021

MyoStrain® Provides Comprehensive Assessment of Myocardial Deformation to Help Physicians Risk-Stratify Heart Failure Patients for Individualized Cardiac Treatment

A new article published in the European Society of Cardiology (ESC) Heart Failure Journal demonstrated MyoStrain’s ability to accurately detect and delineate patterns of myocardial dysfunction between heart failure (HF) types and severity...

Read more >

January 25, 2021

JACC Cardiovascular Imaging Publishes New Peer-Reviewed Article Validating MyoStrain® for the Detection of Asymptomatic Cardiac Dysfunction and Ability to Risk-Stratify Patients for Individualized Care

A new pivotal research paper published in the Journal of American College of Cardiology (JACC) Cardiovascular Imaging presents several key validations for the clinical use of MyoStrain® in determining the risk of heart failure across multiple cardiac disease states.

Read more >